Incorporating some potential obstacles arising from recent Chinese developments
15/09/23 -"Despite Philips gaining confidence, thanks to promising testing results for respiratory devices, improving operations and a big new investor coming on board, our target price resets lower due to ..."
Pages
71
Language
English
Published on
15/09/23
You may also be interested by these reports :
08/10/26
Our target price has increased due to a higher NAV and DCF, along with a 20% premium applied to our peer-based valuation metrics, excluding dividend ...
08/10/26
The TP increase reflects upgrades to our DCF and NAV (discussed above). The investment case remains compelling: consumables-led growth, the ...
08/10/26
Beaten down, not broken.
05/10/26
When we last teased on Fresenius (BUY; Germany) in May 2025, the story was about slimming down: shedding Vamed, deconsolidating FMC and working the ...